Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3027798 | 0.82 | HSD11B1 (0.50) | HSD11B1KMT2AMEN1 | |
| SCHEMBL6680140 | 0.82 | HSD11B1 (0.46) | HSD11B1ALDH1A1OPRM1KMT2AMEN1 | |
| SCHEMBL6895186 | 0.81 | HSD11B1 (0.45) | HSD11B1OPRM1 | |
| SCHEMBL6901003 | 0.78 | MAOA (0.41) | HSD11B1ALDH1A1OPRM1KMT2AMEN1 | |
| SCHEMBL6895204 | 0.78 | HSD11B1 (0.50) | HSD11B1ALDH1A1LMNAMAOAMAOB | |
| SCHEMBL6891957 | 0.72 | HSD11B1 (0.54) | HSD11B1ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL6893766 | 0.70 | HSD11B1 (0.42) | HSD11B1KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL21002203 | 0.67 | KMT2A (0.49) | HSD11B1ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30791158 | 0.67 | KMT2A (0.49) | HSD11B1ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6891948 | 0.67 | HSD11B1 (0.42) | HSD11B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143964-B1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RES LTD (GB) | 2004-03-24 | — | — | EP | disclosed |
| EP-1051392-B1 | ADAMANTANECARBOXIMIDAMIDE DERIVATIVES AND THEIR USE AS NMDA ANTAGONISTS | VERNALIS RES LTD (GB) | 2003-12-17 | — | — | EP | disclosed |
| US-6531511-B1 | N-methyl aspartate receptor antagonist | VERNALIS RESEARCH LIMITED (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1143964-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2001-10-17 | — | — | EP | disclosed |
| US-6262106-B1 | Adamantanecarboximidamide derivatives and their use as NMDA antagonists | VERNALIS RESEARCH LIMITED (GB) | 2001-07-17 | — | — | US | disclosed |
| EP-1051392-A1 | ADAMANTANECARBOXIMIDAMIDE DERIVATIVES AND THEIR USE AS NMDA ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000044371-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
| WO-1999038841-A1 | ADAMANTANECARBOXIMIDAMIDE DERIVATIVES AND THEIR USE AS NMDA ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 1999-08-05 | — | — | WO | disclosed |